A framework for applying health technology assessment in Cyprus: Thoughts, success stories, and recommendations

Value in Health Regional Issues

Volumn 2, Issue 2, 2013, Pages 273-278

  Petrou, Panagiotis ^a   Talias, Michalis A ^a  

^a OPEN UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

Drug's Committee; Evaluation; HTA; Pharmaceuticals; Private sector; Public sector

Indexed keywords

ARTICLE; CYPRUS; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH IMPACT ASSESSMENT; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL;

EID: 84884133898     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2013.06.016     Document Type: Article

References (25)

1. Golna C., Pashardes P., Allin S., et al. Health Care Systems in Transition: Cyprus. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies 2004.
2. Sachs JD. Macroeconomics and Health: Investing in Health for Economic Development. World Health Organization WHO Library Catalogue-in-Publication Data World Health Organization. Geneva, Switzerland: World Health Organization, 2001.
3. Eurostat [online]. Health care statistics, 2009. Available from:. [Accessed September 17, 2011]. http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Healthcare_statistics.
4. Sammoutis G., Paschalides C. Will the sun shine over Cyprus's national health system?. Lancet 2011, 377:29.
5. Antoniadou M. Can Cyprus overcome its health care challenges?. Lancet 2005, 365:1017-1020.
6. Andreou M, Pashardes P, Pashourtidou N. Cost and value of health care in Cyprus. Policy paper. Nicosia: University of Cyprus, 2010. Available from:. [Accessed August 18, 2011]. http://www.ucy.ac.cy/data/ecorece/DOP02-10.
7. Kanavos P., Vandegrift M. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 1997, 41:241-260.
8. Battista R.N., Hodge N.J. The development of health care technology assessment: an international perspective. Int J Technnol Assess Health Care 1995, 11:287-300.
9. Petrou P. PHIS Hospital Pharma Report; 2009. Available from:. [Accessed September 6, 2011]. http://phis.goeg.at/downloads/hospitalPharma/PHIS%20Hospital%20Pharma%20Report%202009%20Cyprus.pdf.
10. Ministry of Health. Pharmaceutical reform in Cyprus. 2006. Available from:. [Accessed September 11, 2011]. http://www.cyprus.gov.cy/moi/pio/pio.nsf/All/BEFF3C4943A9C696C2257127003D66A8?OpenDocument&print.
11. Velasco Garrido M., Gerhardus A., Røttingen J.A., Busse R. Developing health technology assessment to address health care system needs. Health Policy 2010, 94:196-202.
12. Goeree R., He J., O'Reilly D., et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res 2011, 3:89-104.
13. Drug's Committee, Ministry of Health. Terms of reference drug's committee. Available from:. [Accessed June 10, 2013]. http://www.moh.gov.cy/moh/phs/phs.nsf/dmlphcomm_gr/dmlphcomm_gr?OpenDocument.
14. Appraisal of macular degeneration (age-related)-ranibizumab and pegaptanib (TA155). 2008. Available from:. [Accessed December 17, 2011]. http://www.nice.org.uk/TA155.
15. Drummond M., Kanavos P., Sorenson C. Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union 2008, World Health Organization on behalf of the European Observatory on Health Systems and Policies, Denmark.
16. National Institute for Health and Clinical Excellence. Appraising end of life medicines. 2008. Available from:. [Accessed December 17, 2011]. http://www.nice.org.uk/media/26E/43/Endoflifemedicines.pdf.
17. Espín J., Rovira J., García L. Experiences and Impact of European Risk Sharing Schemes Focusing on Oncology Medicines. Grenada, Spain: Andalusian School of Public Health 2011.
18. Stolk A.E., de Bont A., van Halteren A.R., et al. Role of health technology assessment in shaping the benefits package in The Netherlands. Expert Rev Pharmacoecon Outcomes Res 2009, 9:85-94.
19. Dorte Gyrd-Hansen. Willingness to pay for a QALY. Health Econ 2003;12:1049-60.
20. General audit recommendations for rational medicines procurement. 2011. Available from:. [Accessed November 17, 2011]. http://pdf.politis-news.com/pdf/pdf?-A=257761,pdfview.html&-V=pdfarchivefullpaper.
21. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
22. Culyer A.J., Lomas J. Deliberative processes and evidence-informed decision making in healthcare: do they work and how might we know?. Evidence Policy 2006, 2:357-371.
23. Garrido V.M., Kristensen F.B., Nielsen C.P., et al. Health Technology Assessment and Health Policy Making in Europe: Current Status, Challenges and Potentials 2008, World Health Organization, Denmark.
24. Cyprus Ministry of Health. Annual health report, Nicosia; 2010. Available from:. [Accessed June 10, 2013]. http://www.moh.gov.cy/moh/moh.nsf/page09_gr/page09_gr?OpenDocument.
25. Statistical Service of the Republic of Cyprus. Latest figures: GDP growth rate, 1st quarter 2010. Available from:. [Accessed June 8, 2012]. http://www.cystat.gov.cy/mof/cystat/statistics.nsf/All/ADAE80767589A7B9C22579AE0029E929.